Cresilon

Executive Summary

Cresilon is a Brooklyn-based medical device company that has developed a proprietary plant-based hemostatic gel technology capable of stopping traumatic and surgical bleeding within seconds without manual pressure. Founded in 2015, the company targets high-acuity bleeding scenarios in emergency medicine, military/defense, and veterinary care. Its product addresses a critical unmet need in hemorrhage control, where rapid hemostasis can significantly improve survival rates. The technology leverages a novel biocompatible polymer that forms a strong physical barrier, potentially reducing reliance on traditional compression methods and enabling use in difficult-to-access wounds.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for initial product in surgical hemostasis70% success
• Q2 2026Strategic partnership or distribution agreement with major trauma center or military60% success
• Q3 2026Publication of pivotal clinical trial results demonstrating superiority over standard of care50% success